



Uropathogens—Antibiotic Resistance and Alternative Therapies, 2nd Edition

Guest Editors:

Dr. Barbara Kot

Institute of Biological Sciences,
Faculty of Exact and Natural
Sciences, Siedlce University of
Natural Sciences and
Humanities, B. Prusa 14, 08-110
Siedlce, Poland

Dr. Piotr Szweda

Department of Pharmaceutical
Technology and Biochemistry,
Faculty of Chemistry, Gdansk
University of Technology,
Gdansk, Poland

Deadline for manuscript
submissions:

30 June 2024

Message from the Guest Editors

The increase in antibiotic resistance and the appearance of multi-drug resistant (MDR) pathogens in UTIs is associated with high rates of inadequate antibiotic empirical therapies. An understanding of regional differences concerning uropathogens responsible for UTIs and their antibiotic susceptibility is crucial for public health and important in empirical therapy to promote the proper use of existing chemotherapeutics. In addition, there is a urgent priority to find new antimicrobial agents, alternatives to antibiotics or additional prophylactic strategies to control UTIs, including biofilm formation in the urinary tract and on urinary catheters. Among these innovative agents, phytochemicals, preventive vaccines, probiotics, bacteriophages and nanoparticles seem to be the most promising.

Similar to the first edition of this Special Issue, manuscripts presenting all aspects of the challenges of drug resistance to uropathogens, as well as innovative approaches for the treatment of UTIs, are welcome.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)